Adenosine A_2A receptor antagonism protects against hyperoxia-induced retinal vascular loss via cellular proliferation

Area of Science:

• Ophthalmology
• Neonatology
• Molecular Biology

Background:

• Retinopathy of prematurity (ROP) is a leading cause of childhood blindness.
• Current ROP treatments target the hypoxic phase, but early hyperoxia-induced vascular loss is a critical therapeutic window.
• No effective therapeutic strategy currently exists for preventing early hyperoxia-induced retinal vascular damage.

Purpose of the Study:

• To uncover the cellular mechanism of adenosine A2A receptor (A2A R)-mediated protection against early hyperoxia-induced retinal vascular loss.
• To investigate the role of cellular proliferation and adenosine signaling during hyperoxia in retinopathy of prematurity.
• To identify potential therapeutic strategies targeting the hyperoxic phase of ROP.

Main Methods:

• Administered adenosine A2A receptor antagonists during the hyperoxic phase in a mouse model of ROP.
• Analyzed cellular proliferation, apoptosis, and adenosine signaling at different postnatal days (P9 and P12) during hyperoxia.
• Utilized siRNA knockdown of key signaling molecules (e.g., vascular endothelial growth factor-A) to validate the role of cellular proliferation.

Main Results:

• Identified two distinct stages of hyperoxia with differential cellular activities and adenosine signaling.
• Demonstrated that A2A R antagonism at postnatal day 9 (P9) reversed hyperoxia-induced inhibition of progenitor cells and retinal endothelial proliferation.
• Confirmed the critical role of cellular proliferation in hyperoxia-induced retinal vascular loss.

Conclusions:

• Adenosine A2A receptor antagonists offer a promising therapeutic strategy for preventing early hyperoxia-induced retinal vascular loss in ROP.
• Targeting cellular proliferation during the hyperoxic phase is crucial for ROP prevention.
• Understanding the distinct stages of hyperoxia is key to developing effective ROP treatments.